Pharmaceutical Company Allegedly Involved In Kickback Scheme For Opioid Medication

Case Overview

This case involves a pharmaceutical company allegedly involved in a widespread kickback scheme in which they were paying physicians to prescribe an opioid pain medication. It was suggested that the company fraudulently marketed this drug for off-label use and employed improper warning practices when promoting the drug. An expert was sought to opine on the research related to the speaker programs many big pharma companies have implemented, along with the potential relationship between the drug’s promotion and kickback programs for physicians.